Table 2 Comparison of histological classifications and the abnormalities observed in the in vitro analysis of each iPSC-NSPC line
NSPCs | Abnormality in in vitro analysis | Number of animals for each experiment (histology taken at 3Â months/ 6Â months) | Percentage of neural differentiation seen in each experiment | |||
|---|---|---|---|---|---|---|
(histology taken at 3Â months/6Â months) | ||||||
| Â | Â | Spinal cord | Graft failure | DNT | UDNT | BLT |
| Â | Â | Brain | Â | Â | Â | Â |
1210B2 EB-NSPCs | CNV (no de novo, very few additional) | 3/2 | None | 100Â %/100Â % | 33Â %/0Â % | 33Â %/0Â % |
(n = 3/2) | (n = 1/0) | (n = 1/0) | ||||
3/2 | None | 100Â %/100Â % | None | None | ||
(n = 3/2) | ||||||
1210B2 NR-NSPCs | CNV (one de novo, very few additional) | 3/2 | 33Â %/0Â % | 0Â %/ 100Â % | 33Â %/0Â % | 67Â %/0Â % |
(n = 1/0) | (n = 0/2) | (n = 1/0) | (n = 2/0) | |||
3/2 | None | 100Â %/100Â % | None | None | ||
(n = 3/2) | ||||||
1231A3 EB-NSPCs | CNV (many de novo, some additional) | 2/3 | 0Â %/33Â % | 100Â %/67Â % | 100Â %/67Â % | 0Â %/33Â % |
(n = 0/1) | (n = 2/2) | (n = 2/2) | (n = 0/1) | |||
3/3 | None | 100Â %/100Â % | 67Â %/100Â % | None | ||
(n = 3/3) | (n = 2/3) | |||||
1231A3 NR-NSPCs | Karyotype CNV (many de novo, many additional) | 3/3 | None | 67Â %/100Â % | 33Â %/0Â % | 33Â %/0Â % |
(n = 2/3) | (n = 1/0) | (n = 1/0) | ||||
3/3 | None | 100Â %/100Â % | None | None | ||
(n = 3/3) | ||||||
1201C1 EB-NSPCs | CNV (some de novo, no additional) | 3/0 | None | 100Â % /- | 33.3Â %/- | None |
(n = 3/-) | (n = 1/-) | |||||
3/3 | None | 100Â %/100Â % | 0Â %/67Â % | None | ||
(n = 3/3) | (n = 0/2) | |||||
1201C1 NR-NSPCs | CNV (some de novo, no additional) | 3/3 | 33Â %/67Â % | 67Â %/33Â % | 33Â %/0Â % | None |
(n = 1/2) | (n = 2/1) | (n = 1/0) | ||||
5/1 | None | 100Â % /100Â % | None | None | ||
(n = 5/1) | ||||||